Dai Xuan, Li Yifan, Wang Haoran, Dai Zhujiang, Chen Yuanyuan, Liu Yun, Huang Shiyong
Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Gastrointestinal Surgery, Huaihe Hospital of Henan University, Kaifeng, Henan, China.
Front Oncol. 2024 Oct 11;14:1402847. doi: 10.3389/fonc.2024.1402847. eCollection 2024.
Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are the predominant serum tumour markers (STMs) for predicting the prognosis of colorectal cancer (CRC). The objective of this research is to develop clinical prediction models based on preoperative and postoperative CEA and CA19-9 levels.
1,452 consecutive participants with stage I-III colorectal cancer were included. Kaplan-Meier method, log-rank test, and multivariate COX regression were used to evaluate the significance of preoperative and postoperative STMs. Patients were grouped into a discovery cohort (70%) and a validation cohort (30%). Variables for the nomograms were selected according to the Akaike information criterion (AIC). Subsequently, two clinical predictive models were constructed, evaluated, validated, and then compared with the AJCC 8th TNM stage.
The overall survival (OS) rate and disease-free survival(DFS) rate declined progressively as the number of positive tumour markers(NPTMs) before and after surgery increased. For both OS and DFS, age, sex, pN stage, and NPTMs before and after surgery were independent prognostic factors, and then clinical prediction models were developed. The Concordance index (C-index), Receiver operating characteristic (ROC) curve, calibration curve, Decision curve analysis (DCA), and risk score stratification all indicated that the models possessed robust predictive efficacy and clinical applicability. The Net reclassification index (NRI) and Integrated discrimination improvement (IDI) indicated that the performance of models was significantly superior to the TNM stage.
Nomograms based on pre-and postoperative CEA and CA19-9 can accurately predict survival and recurrence for stage I-III CRC patients after radical surgery, and were significantly better than the AJCC 8th TNM stage.
癌胚抗原(CEA)和糖类抗原19-9(CA19-9)是预测结直肠癌(CRC)预后的主要血清肿瘤标志物(STM)。本研究的目的是基于术前和术后CEA及CA19-9水平建立临床预测模型。
纳入1452例连续的I-III期结直肠癌患者。采用Kaplan-Meier法、对数秩检验和多因素COX回归评估术前和术后STM的意义。患者被分为发现队列(70%)和验证队列(30%)。根据赤池信息准则(AIC)选择列线图的变量。随后,构建、评估、验证两个临床预测模型,然后与美国癌症联合委员会(AJCC)第8版TNM分期进行比较。
随着手术前后阳性肿瘤标志物数量(NPTM)的增加,总生存率(OS)和无病生存率(DFS)逐渐下降。对于OS和DFS,年龄、性别、pN分期以及手术前后的NPTM均为独立预后因素,进而建立了临床预测模型。一致性指数(C指数)、受试者工作特征(ROC)曲线、校准曲线、决策曲线分析(DCA)和风险评分分层均表明模型具有强大的预测效能和临床适用性。净重新分类指数(NRI)和综合判别改善(IDI)表明模型的性能显著优于TNM分期。
基于术前和术后CEA及CA19-9的列线图能够准确预测I-III期CRC患者根治性手术后的生存和复发情况,且显著优于AJCC第8版TNM分期。